Daily Derm Times: May 13, 2025

Author(s):

Emma Andrus, Editor

Key Takeaways

IL-13 and IL-31 inhibitors provide distinct yet complementary mechanisms for atopic dermatitis management, enhancing treatment strategies.
JAK inhibitors in vitiligo management show promising efficacy and safety, with potential for combination therapies.
Despite social media's influence, patients trust dermatologists over influencers for acne treatment guidance.
A novel botanical-based nutraceutical significantly improves mild to moderate acne, offering a holistic treatment approach.
TRIV-509 and Tyk2 inhibition present promising strategies for atopic dermatitis and type 1 diabetes by targeting inflammation and restoring skin integrity.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Experts Look Ahead to the Advancements in AD Research

To hear more about AD advancements from Shahriari and Lio in person, register to attend the Revolutionizing Atopic Dermatitis Conference 2025 in Nashville, Tennessee, on June 6 and 7.

What to Know When Targeting IL-13 vs IL-31 in Atopic Dermatitis

Raj Chovatiya, MD, PhD, MSCI, discusses how IL-13 and IL-31 inhibitors represent distinct yet complementary mechanisms in the management of atopic dermatitis.

New Meta-Analysis Supports Targeted Vitiligo Therapies

Explore the promising role of JAK inhibitors in vitiligo management, highlighting efficacy, safety, and potential combination therapies for enhanced results.

New Survey Confirms Acne Patients Have More Trust in Clinicians than Social Media Influencers

Even with the recent rise of social media guidance, patients still trust dermatologists over social media influencers for acne treatment.

Botanical-Based Nutraceutical Improves Acne

Discover how a novel nutraceutical significantly improves mild to moderate acne in a 12-week clinical trial, offering a holistic approach to skin health.

Dual Inhibitor TRIV-509 Shows Promise for Rapid Improvement in Atopic Dermatitis

Researchers reveal TRIV-509, a novel monoclonal antibody, shows promise in rapidly improving atopic dermatitis by restoring skin barrier integrity and reducing inflammation.

Tyk2 Inhibition Prevents Islet Inflammation and Delays Type 1 Diabetes Development in Mice

New research reveals a promising strategy to slow type 1 diabetes progression by targeting inflammation with an existing psoriasis drug.

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!